The nasal mucosal late allergic reaction to grass pollen involves type 2 inflammation (IL-5 and IL-13), the inflammasome (IL-1β), and complement.
A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients.
A novel flow cytometric-based method to measure kinase inhibition in sputum from COPD subjects.
Using magnetic resonance imaging to quantify the inflammatory response following allergen challenge in allergic rhinitis.
Bronchoabsorption; a novel bronchoscopic technique to improve biomarker sampling of the airway.
The novel inhaled glucocorticoid receptor agonist GW870086X protects against adenosine-induced bronchoconstriction in asthma.
The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild to moderate asthma.
Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease.
The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthmatics.
Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics.
Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist.
Rapid effects of extrafine beclomethasone dipropionate/formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial.
Safety of Regadenoson, an A2A receptor agonist for myocardial perfusion imaging in asthmatic patients: a randomised double blind placebo controlled trial.